Brief: First Wave Biopharma Announces Phase 2 Adrulipase Combination Trial Data To Be Presented At The 2023 Digestive Disease Week (Ddw) Conference
21/02/2023 12:14
Feb 21 (Reuters) - First Wave BioPharma Inc FWBI.O :
* FIRST WAVE BIOPHARMA ANNOUNCES PHASE 2 ADRULIPASE
COMBINATION
TRIAL DATA TO BE PRESENTED AT THE 2023 DIGESTIVE DISEASE WEEK
(DDW) CONFERENCE
Source text for Eikon: ID:nGNX714CDv
Further company coverage: FWBI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on GridAI Technologies
See all newsBrief: Gridai Technologies Corp - Enters $2.54 Million Private Placement Of Shares And Warrants - SEC Filing
Brief: IBN Announces Latest Episode Of The Techmediawire Podcast Featuring Marshall Chapin, CEO Of Grid Ai Corp.
Brief: Entero Therapeutics Terminated Interim CEO And Chairman Richard Joel Paolone Effective Immediately - SEC Filing
Brief: Entero Therapeutics Inc - Now Offering 15.2 Million Shares Of Common Stock
Brief: Entero Therapeutics Inc Subsidiary Immunogenx Enters Settlement Agreement